

## Invitrocue appoints Prof Arial Zeng Yi as Patient Derived Organoid Consultant

18 February 2019 | News

Prof Zeng is an expert in the study of mammary stem cell and breast cancer for the purposes of regenerative and cancer medicine



Invitrocue, a leading healthcare bio-analytic solutions provider, is pleased to announce the appointment of Professor Arial Zeng Yi as Patient Derived Organoid (PDO) Consultant. Professor Zeng is currently Principal Investigator at Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS).

She is an expert in the study of mammary stem cell and breast cancer for the purposes of regenerative and cancer medicine. Prof. Zeng holds a postdoctoral degree in Developmental Biology from Stanford University. She has authored and coauthored various research papers on mammary development, multipotent mammary stem cells and breast cancer.

Professor Zeng is currently spearheading Invitrocue's collaboration with the SIBCB to propagate and expand PDOs from breast cancer patients with multiple breast cancer subtypes, including ER+, PR+, HER2+ and TNBC. Her work with the company will enable Invitrocue to optimise the testing protocols for breast cancer models and expedite the expansion of its Onco-PDOTM cancer indication menu for Invitrocue's proprietary Onco-PDOTM test.

As a consultant to Invitrocue, Prof. Zeng will also provide insights on breast cancer and oncology treatments as the company seeks to continue to broaden the applicability of the Onco-PDO™ personalised screening test.

Commenting on the appointment of Prof. Zeng, Dr. Steven Fang, Executive Chairman, Invitrocue, said: "We are delighted to welcome Professor Arial Zeng to Invitrocue as a consultant. Her research into organoids, specifically in breast cancer, is world-leading and will be of great benefit to Invitrocue as we focus on broadening the indication menu of Onco-PDOTM. Working closely with our advisors and consultants like Professor Zeng, we are also continually broadening our network to educate key opinion leaders on the role of OncoPDOTM as a key tool in evidence-based decision making for cancer treatments."